Calidi Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
CLDI$0.73+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| Exhibit No. | Description |
| 4.1 | Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Form 8-K filed with the SEC on January 10, 2025) |
| 4.2 | Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed with the SEC on April 1, 2025) |
| 4.3 | Form of Series G Common Warrant (incorporated by reference to Exhibit 4.2 to the Form 8-K filed with the SEC on April 1, 2025) |
| 4.4 | Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Form 8-K filed with the SEC on April 1, 2025) |
| 10.1 | Form of Placement Agency Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on January 10, 2025) |
| 10.2 | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on April 1, 2025) |
| 10.3 | Form of Placement Agency Agreement (incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on April 1, 2025) |
| 10.4 | General Release of Claims and Transition Agreement by and between the Company and Allan Camaisa dated April 21, 2025 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on April 23, 2025) |
| 10.5 | Executive Employment Agreement by and between the Company and Eric Poma dated April 22, 2025 (incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on April 23, 2025) |
| 31.1* | Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1** | Certificate of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2** | Certificate of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Inline XBRL Instance Document |
| 101. SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Filed herewith |
|---|---|
| ** | Furnished herewith. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.